SCHEMBL5467463

SCHEMBL5467463

COc1cc(C)ccc1NC(=O)Nc1ccc(N2CCN(C(=O)Nc3ncccc3C)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.51
RAB9A P51151 7/20 0.50
NPC1 O15118 6/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
KDM4E B2RXH2 3/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
MAPT P10636 5/20 0.48
TRPV1 Q8NER1 2/20 0.47
LCK P06239 1/20 0.45
PDGFRB P09619 1/20 0.45
ALDH1A1 P00352 3/20 0.45
USP2 O75604 1/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
LMNA P02545 1/20 0.45
NAMPT P43490 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5467111 0.93 MAPT (0.51) GFERRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL5467032 0.89 PANK3 (0.46) RAB9ANPC1KDM4EL3MBTL1MAPT
SCHEMBL5467464 0.88 GFER (0.51) GFERRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL5453308 0.86 GFER (0.53) GFERRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL5470998 0.86 RAB9A (0.53) GFERRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL5465363 0.85 RAB9A (0.52) GFERRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL5456879 0.85 RAB9A (0.59) RAB9ANPC1SMN1; SMN2KDM4EL3MBTL1
SCHEMBL5465476 0.85 MAPT (0.49) RAB9ANPC1SMN1; SMN2NPSR1MAPT
SCHEMBL5462743 0.85 RBP4 (0.56) RAB9ANPC1SMN1; SMN2MAPTTRPV1
SCHEMBL5455789 0.84 ALK (0.51) RAB9ANPC1SMN1; SMN2MAPTLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 GFER 1367/4885RAB9A 1528/4885NPC1 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.